DLH Reports Fourth Quarter and Fiscal Year 2020 Results
DLH Holdings Corp. (NASDAQ: DLHC) reported fiscal 2020 annual revenue of $209.2 million, up from $160.4 million in 2019, driven by new awards and acquisitions despite COVID-19 impacts. Earnings increased to $0.54 per diluted share from $0.41. Cash flow from operations reached $19.5 million, with a significant debt reduction of $19 million. The acquisition of Irving Burton Associates (IBA) for $32 million added over $140 million to the company’s backlog of $688.4 million.
- Annual revenue increased by 30.4% to $209.2 million.
- Earnings per share rose to $0.54 from $0.41.
- Cash flow from operations was $19.5 million.
- Debt reduced by $19 million during fiscal 2020.
- Backlog increased by 66.2% to $688.4 million.
- Fourth quarter revenue decreased to $50.7 million from $54.2 million.
- Operating margin declined to 5.3% from 6.3% year-over-year.
- Net income for Q4 decreased to $1.4 million from $1.6 million.
Completes Acquisition of IBA; Finishes Fiscal 2020 with Annual Revenue of
ATLANTA, Dec. 07, 2020 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare services and solutions to federal agencies, today announced financial results for its fiscal fourth quarter ended September 30, 2020.
Highlights of Fiscal Year 2020
- Annual revenue rose to
$209.2 million in fiscal 2020 from$160.4 million in fiscal 2019, reflecting growth in key programs, new awards, and recent acquisitions, more than offsetting the impact from COVID-19 on certain programs and services. - Earnings were
$7.1 million , or$0.54 per diluted share, for fiscal 2020 versus$5.3 million , or$0.41 per diluted share, for the prior-year period. - Operating cash flow was
$19.5 million for the fiscal year; senior bank debt was reduced by$19.0 million during fiscal 2020 and by$33.0 million since the June 2019 acquisition, resulting in a debt balance of$37.0 million , prior to closing the IBA transaction. - On September 30, 2020, the Company completed the acquisition of Irving Burton Associates (“IBA”), a leading provider of technology-enabled military health solutions, for
$32.0 million . - The Company's backlog strengthened to
$688.4 million at fiscal year end, following the successful Head Start recompete and the acquisition of IBA.
Management Discussion
“With fiscal 2020 now behind us, I’m proud to say that DLH has, once again, performed very well under rather unpredictable and challenging circumstances – solidifying its leadership position in the federal markets we serve,” stated DLH President and Chief Executive Officer Zach Parker. “Revenue for the year topped
“In addition, we just completed the acquisition of Irving Burton Associates, significantly improving our position within several key military agencies and bolstering our capabilities in research and engineering, data analytics, and artificial intelligence. With this latest transaction under our belt – which brought a backlog of over
Results for the Three Months Ended September 30, 2020
Revenue for the fourth quarter of fiscal 2020 was
Income from operations was
For the three months ended September 30, 2020 and 2019, DLH recorded a
On a non-GAAP basis, EBITDA for the three months ended September 30, 2020 was approximately
Key Financial Indicators
DLH generated
As of September 30, 2020, the Company had cash and cash equivalents of
At September 30, 2020, total backlog was approximately
Fiscal Year 2021 Expectations for Non-Operational Expenses
The Company expects interest expense of approximately
Conference Call and Webcast Details
DLH management will discuss fourth quarter results and provide a general business update, including current competitive conditions and strategies, during a conference call beginning at 11:00 AM Eastern Time on December 7, 2020. Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256. Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call.
A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 877-344-7529 and entering the conference ID 10149431.
About DLH
DLH (NASDAQ:DLHC) ) is a comprehensive health solutions and services provider that delivers a full range of technology-enabled health services across various civilian agencies, the military health system, and the Veterans Administration. The Company's services range from providing virtual pharmacy health consultation for CHAMPVA beneficiaries to veteran pharmacy fulfillment and medical logistics; conducting scientific research and clinical trials toward disease prevention and health promotion; performing medical research and development and enhancing health information technology systems (including telemedicine and electronic health records); and evaluating policy deployment and compliance with applicable protocols and guidelines, with a goal of enhancing the Company's readiness posture while providing safe, effective and integrated solutions and services to the public, armed service members, and veterans who have secured this nation's freedom. DLH has over 2,200 employees serving numerous government agencies. For more information, visit the corporate website at www.dlhcorp.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding estimates of future revenues, operating income, earnings and cash flow. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors, including: the outbreak of the novel coronavirus (“COVID-19”), including the measures to reduce its spread, and its impact on the economy and demand for our services, are uncertain, cannot be predicted, and may precipitate or exacerbate other risks and uncertainties; the risk that we will not realize the anticipated benefits of the IBA or any future acquisition; the challenges of managing larger and more widespread operations resulting from the acquisition; contract awards in connection with re-competes for present business and/or competition for new business; compliance with new bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid protest, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the ability to successfully integrate the operations our recent acquisition and any of future acquisitions; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2020, as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.
CONTACTS:
INVESTOR RELATIONS |
Contact: Chris Witty |
Phone: 646-438-9385 |
Email: cwitty@darrowir.com |
TABLES TO FOLLOW
DLH HOLDINGS CORP.
CONSOLIDATED STATEMENTS OF INCOME
(Amounts in thousands except per share amounts)
Three Months Ended | Twelve Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
Revenue | $ | 50,691 | $ | 54,183 | $ | 209,185 | $ | 160,391 | ||||||||
Cost of Operations: | ||||||||||||||||
Contract costs | 39,701 | 41,803 | 163,596 | 124,551 | ||||||||||||
General and administrative costs | 5,698 | 7,067 | 24,195 | 20,525 | ||||||||||||
Acquisition costs | 930 | — | 930 | 1,391 | ||||||||||||
Depreciation and amortization | 1,664 | 1,919 | 7,003 | 3,956 | ||||||||||||
Total operating costs | 47,993 | 50,789 | 195,724 | 150,423 | ||||||||||||
Income from operations | 2,698 | 3,394 | 13,461 | 9,968 | ||||||||||||
Interest expense, net | 781 | 1,190 | 3,441 | 2,473 | ||||||||||||
Income before income taxes | 1,917 | 2,204 | 10,020 | 7,495 | ||||||||||||
Income tax expense | 554 | 639 | 2,906 | 2,171 | ||||||||||||
Net income | $ | 1,363 | $ | 1,565 | $ | 7,114 | $ | 5,324 | ||||||||
Net income per share - basic | $ | 0.11 | $ | 0.13 | $ | 0.58 | $ | 0.44 | ||||||||
Net income per share - diluted | $ | 0.10 | $ | 0.12 | $ | 0.54 | $ | 0.41 | ||||||||
Weighted average common shares outstanding | ||||||||||||||||
Basic | 12,390 | 12,036 | 12,282 | 12,018 | ||||||||||||
Diluted | 13,356 | 13,016 | 13,105 | 13,041 | ||||||||||||
DLH HOLDINGS CORP.
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands except par value of shares)
September 30, 2020 | September 30, 2019 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 1,357 | $ | 1,790 | ||||
Accounts receivable | 32,541 | 23,226 | ||||||
Other current assets | 3,499 | 1,831 | ||||||
Total current assets | 37,397 | 26,847 | ||||||
Equipment and improvements, net | 3,339 | 5,343 | ||||||
Operating lease right-of-use assets | 22,427 | — | ||||||
Deferred taxes, net | 37 | 2,345 | ||||||
Goodwill | 67,144 | 52,758 | ||||||
Intangible assets, net | 52,612 | 41,208 | ||||||
Other long-term assets | 606 | 757 | ||||||
Total assets | $ | 183,562 | $ | 129,258 | ||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Debt obligations - current, net of deferred financing costs | $ | 6,727 | $ | — | ||||
Operating lease liabilities - current | 2,045 | — | ||||||
Accrued payroll | 10,611 | 8,852 | ||||||
Accounts payable, accrued expenses, and other current liabilities | 28,578 | 20,633 | ||||||
Total current liabilities | 47,961 | 29,485 | ||||||
Long-term liabilities: | ||||||||
Operating lease liabilities - long-term | 21,620 | — | ||||||
Debt obligations - long term, net of deferred financing costs | 60,544 | 53,629 | ||||||
Other long-term liabilities | — | 573 | ||||||
Total long-term liabilities | 82,164 | 54,202 | ||||||
Total liabilities | 130,125 | 83,687 | ||||||
Shareholders' equity: | ||||||||
Common stock, | 12 | 12 | ||||||
Additional paid-in capital | 85,868 | 85,114 | ||||||
Accumulated deficit | (32,443 | ) | (39,555 | ) | ||||
Total shareholders’ equity | 53,437 | 45,571 | ||||||
Total liabilities and shareholders' equity | $ | 183,562 | $ | 129,258 | ||||
DLH HOLDINGS CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
Twelve Months Ended | ||||||||
September 30, | ||||||||
2020 | 2019 | |||||||
Operating activities | ||||||||
Net income | $ | 7,114 | $ | 5,324 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization expense | 7,003 | 3,956 | ||||||
Amortization of deferred financing costs | 721 | 982 | ||||||
Stock based compensation expense | 910 | 790 | ||||||
Deferred taxes, net | 2,308 | 1,792 | ||||||
Non-cash gain from lease modification | (121 | ) | — | |||||
Changes in operating assets and liabilities | ||||||||
Accounts receivable | (5,408 | ) | 617 | |||||
Other current assets | (1,592 | ) | (57 | ) | ||||
Accrued payroll | 489 | 178 | ||||||
Accounts payable, accrued expenses, and other current liabilities | 7,188 | 5,262 | ||||||
Other long-term assets/liabilities | 839 | (805 | ) | |||||
Net cash provided by operating activities | 19,451 | 18,039 | ||||||
Investing activities | ||||||||
Business acquisition, net of cash acquired | (32,678 | ) | (67,079 | ) | ||||
Purchase of equipment and improvements | (152 | ) | (405 | ) | ||||
Net cash used in investing activities | (32,830 | ) | (67,484 | ) | ||||
Financing activities | ||||||||
Borrowing on senior debt | 33,000 | 70,000 | ||||||
Repayments of senior debt | (19,000 | ) | (21,708 | ) | ||||
Repurchase of common stock | (211 | ) | — | |||||
Payment of deferred financing costs | (898 | ) | (3,451 | ) | ||||
Proceeds from issuance of common stock upon exercise of options | 55 | 39 | ||||||
Net cash provided by financing activities | 12,946 | 44,880 | ||||||
Net change in cash and cash equivalents | (433 | ) | (4,565 | ) | ||||
Cash and cash equivalents at beginning of year | 1,790 | 6,355 | ||||||
Cash and cash equivalents at end of year | $ | 1,357 | $ | 1,790 | ||||
Supplemental disclosures of cash flow information | ||||||||
Cash paid during the period for interest | $ | 2,806 | $ | 1502 | ||||
Cash paid during the period for income taxes | $ | 917 | $ | 543 | ||||
Revenue Metrics
Twelve Months Ended | ||||||
September 30, | September 30, | |||||
2020 | 2019 | |||||
Market Mix: | ||||||
Defense/VA | 49 | % | 58 | % | ||
Human Services and Solutions | 20 | % | 25 | % | ||
Public Health/Life Sciences | 31 | % | 17 | % | ||
Contract Mix: | ||||||
Time and materials | 70 | % | 84 | % | ||
Cost reimbursable | 28 | % | 14 | % | ||
Firm fixed price | 2 | % | 2 | % | ||
Prime vs Sub: | ||||||
Prime | 92 | % | 96 | % | ||
Subcontractor | 8 | % | 4 | % | ||
Non-GAAP Financial Measures
The Company uses EBITDA and EBITDA as a percent of revenue as supplemental non-GAAP measures of performance. We define EBITDA as net income excluding (i) interest expense, (ii) provision for or benefit from income taxes and (iii) depreciation and amortization. EBITDA as a percent of revenue is EBITDA for the measurement period divided by revenue for the same period.
The Company incurred
These non-GAAP measures of performance are used by management to conduct and evaluate its business during its review of operating results for the periods presented. Management and the Company's Board utilize these non-GAAP measures to make decisions about the use of the Company's resources, analyze performance between periods, develop internal projections and measure management performance. We believe that these non-GAAP measures are useful to investors in evaluating the Company's ongoing operating and financial results and understanding how such results compare with the Company's historical performance.
Reconciliation of GAAP net income to EBITDA, a non-GAAP measure:
(amounts in thousands) | Three Months Ended | Twelve Months Ended | ||||||||||||||||||||||||
September 30, | September 30, | |||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | |||||||||||||||||||||
Net income | $ | 1,363 | $ | 1,565 | $ | (202 | ) | $ | 7,114 | $ | 5,324 | $ | 1,790 | |||||||||||||
(i) Interest expense, net | 781 | 1,190 | (409 | ) | 3,441 | 2,473 | 968 | |||||||||||||||||||
(ii) Provision for taxes | 554 | 639 | (85 | ) | 2,906 | 2,171 | 735 | |||||||||||||||||||
(iii) Depreciation and amortization | 1,664 | 1,919 | (255 | ) | 7,003 | 3,956 | 3,047 | |||||||||||||||||||
EBITDA | $ | 4,362 | $ | 5,313 | $ | (951 | ) | $ | 20,464 | $ | 13,924 | $ | 6,540 | |||||||||||||
Net income as a % of revenue | 2.7 | % | 2.9 | % | (0.2 | )% | 3.4 | % | 3.3 | % | 0.1 | % | ||||||||||||||
EBITDA as a % of revenue | 8.6 | % | 9.8 | % | (1.2 | )% | 9.8 | % | 8.7 | % | 1.1 | % | ||||||||||||||
Revenue | $ | 50,691 | $ | 54,183 | $ | (3,492 | ) | $ | 209,185 | $ | 160,391 | $ | 48,794 | |||||||||||||
Reconciliation of GAAP net income to net income adjusted for the effect of acquisition costs, a non-GAAP measure:
Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||
September 30, | September 30, | |||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | |||||||||||||||||||
Net income | $ | 1,363 | $ | 1,565 | $ | (202 | ) | $ | 7,114 | $ | 5,324 | $ | 1,790 | |||||||||||
Acquisition costs | 930 | — | 930 | 930 | 1,391 | (461 | ) | |||||||||||||||||
Tax effect of excluding acquisition costs | (270 | ) | — | (270 | ) | (270 | ) | (403 | ) | 133 | ||||||||||||||
Net income adjusted for the acquisition costs | $ | 2,023 | $ | 1,565 | $ | 458 | $ | 7,774 | $ | 6,312 | $ | 1,462 | ||||||||||||
Net income per diluted shares outstanding | $ | 0.10 | $ | 0.12 | $ | (0.02 | ) | $ | 0.54 | $ | 0.41 | $ | 0.13 | |||||||||||
Impact of acquisition costs, net | 0.05 | — | 0.05 | 0.05 | 0.08 | (0.03 | ) | |||||||||||||||||
Net income per diluted shares adjusted for the acquisition costs | $ | 0.15 | $ | 0.12 | $ | 0.03 | $ | 0.59 | $ | 0.49 | $ | 0.10 | ||||||||||||
Weighted average of diluted common shares outstanding | 13,356 | 13,016 | 13,105 | 13,041 |
FAQ
What were DLHC's annual revenue and earnings for fiscal 2020?
What was the impact of COVID-19 on DLHC's fiscal 2020 performance?
What acquisitions did DLHC complete during fiscal 2020?
How much did DLHC reduce its debt in fiscal 2020?